Indexing
CÁC SỐ TỪ 2011-2023
Tạp chí Y Dược Học
Abstract
Objective: To determine the rate of achieving non-high-density lipoprotein cholesterol (Non-HDL-C) goals and related factors in patients with obstructive coronary artery disease (CAD).
Methods: A cross-sectional study was conducted on 226 patients (mean age 64.72 ± 8.02 years, 69% male) diagnosed with stable angina and obstructive CAD via coronary computed tomography angiography. Obstructive CAD was defined as ≥ 50% diameter stenosis in at least one of epicardial coronary arteries. Blood lipid panels were performed within 24 hours of hospitalizatiion. The Non-HDL-C goal was defined as < 2.6 mmol/L for the high-risk group.
Results: The proportion of patients on statin therapy was 72.57%, with 64.16% of patients using statins > 3 months. The median Non-HDL-C level was 3.1 mmol/L (interquartile range: 2.47 - 4.26). The rate of achieving Non-HDL-C control goal was 27.88% (n = 63). Compared to patients who achieved Non-HDL-C target, those who did not had higher body mass index (p = 0.022), hypertension rates (p = 0.003), diabetes mellitus (p = 0.025), dyslipidemia (p < 0.001), uric acid level (p = 0.024), total cholesterol (p < 0.001), LDL-C (p < 0.001), triglyceride (p = 0.003), and were more likely to be on statin or statin plus ezetimibe therapy (p < 0.001), and had a longer duration of statin use from 3-12 months or more (p < 0.001). Multivariate regression analysis revealed that hypertension (odds ratio [OR] 0.38, 95% confidence interval [CI] 0.16 - 0.89, p = 0.027), statin therapy duration of 3 - 12 months (OR 2.26, 95% CI 1.05 - 4.88, p = 0.038), statin plus ezetimibe therapy (OR 4.48, 95% CI 1.25 - 16.04, p = 0.021), LDL-C < 1.8 mmol/L (OR 9.74, 95% CI 4.26 - 22.25, p < 0.001), and triglyceride < 1.7 mmol/L (OR 4.30, 95% CI 1.90 - 9.76, p < 0.001) were independent predictors of achiving the Non-HDL-C goal.
Conclusion: Approximately one-third of patients with obstructive CAD achieved the Non-HDL-C goal. Hypertension, duration of statin therapy, combined statin and ezetimibe therapy, and achieving target LDL-C and triglyceride levels were independent predictors of achiving Non-HDL-C goal.
| Published | 2026-03-30 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 1 (2026) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2026.1.1030 | |
| Keywords | bệnh tim thiếu máu cục bộ có tắc nghẽn, non-HDL-C, statin obstructive coronary artery disease, Non-HDL-C, statin |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Hue Journal of Medicine and Pharmacy
Leipsic J, Abbara S, Achenbach S, et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2014;8(5):342-358.
Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93-e621.
Nguyễn Lân Việt, Phạm Việt Tuân, Phạm Mạnh Hùng, Văn Đức Hạnh, Nguyễn Ngọc Quang. Nghiên cứu mô hình bệnh tật ở bệnh nhân điều trị nội trú tại Viện Tim mạch Việt Nam trong thời gian 2003-2007. Tim mạch học Việt Nam. 2010;52:11-18.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188.
Reddy S, Rao K R, Kashyap JR, et al. Association of non-HDL cholesterol with plaque burden and composition of culprit lesion in acute coronary syndrome. An intravascular ultrasound-virtual histology study. Indian Heart J. 2024;76(5):342-348.
Taddei C, Zhou B, Bixby H, et al. Repositioning of the global epicentre of non-optimal cholesterol. Nature. 2020;582(7810):73-77.
Fruchart JC, Davignon J, Hermans MP, et al. Residual macrovascular risk in 2013: What have we learned? Cardiovasc Diabetol. 2014;13:26.
Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302-1309.
Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol. 2021;77(11):1439-1450.
Bộ Y tế. Thực Hành Chẩn Đoán và Điều Trị Bệnh Động Mạch Vành. 2020.
Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019;139(18):E891-E908.
Hoàng Huy Trường, Đặng Quang Minh, Đặng Duy Phương. Đặc điểm của chỉ số NON-HDL-C/HDL-C và mối liên quan với mức độ tổn thương động mạch vành ở bệnh nhân bệnh tim thiếu máu cục bộ có tắc nghẽn. Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế. 2025;17(1):25–33.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150.
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-271.
Parascandola M, Augustson E, Rose A. Characteristics of current and recent former smokers associated with the use of new potential reduced-exposure tobacco products. Nicotine Tob Res. 2009;11(12):1431-1438.
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.
American Diabetes Association. Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. Clin Diabetes. 2022;40(1):10-38.
Đặng Vạn Phước, Phạm Gia Khải, Nguyễn Lân Việt, Huỳnh Văn Minh, Đỗ Doãn Lợi, Phạm Nguyễn Vinh. Khuyến cáo về chẩn đoán và điều trị rối loạn Lipid máu của Hội Tim mạch học Quốc gia Việt Nam 2015. 2015;1–30.
Kavey REW, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003;107(11):1562-1566.
Aboyans V, Ricco JB, Bartelink MLEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763-816.
Michos ED, Choi AD. Coronary Artery Disease in Young Adults: A Hard Lesson But a Good Teacher. J Am Coll Cardiol. 2019;74(15):1879-1882.
Borghi C, Domienik-karłowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update. Cardiol J. 2021;28(1):1-14.
Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80(14):1366-1418.
Karalis DG, Subramanya RD, Hessen SE, Liu L, Victor MF. Achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol. 2011;107(6):886-890.
Virani SS, Woodard LD, Landrum CR, et al. Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J. 2011;161(6):1140-1146.
Võ Thị Dễ, Trương Quang Bình, Võ Thành Nhân, Trần Đức Phấn, Đặng Vạn Phước. Khảo sát điều trị, tuân thủ điều trị rối loạn lipid máu ở bệnh nhân bệnh mạch vành tại Bệnh viện Chợ Rẫy và Bệnh viện Đại học Y dược Thành phố Hồ Chí Minh năm 2007-2008. Tạp chí Y học thực hành. 2011;2(751):18-21.
Wang B, Guo Z, Li H, et al. Non-HDL cholesterol paradox and effect of underlying malnutrition in patients with coronary artery disease: A 41,182 cohort study. Clin Nutr. 2022;41(3):723-730.
Van Der Linde NAJ, Sijbrands EJG, Boomsma F, Van Den Meiracker AH. Effect of low-density lipoprotein cholesterol on angiotensin II sensitivity: A randomized trial with fluvastatin. Hypertension. 2006;47(6):1125-1130.
Hoàng Văn Sỹ, Lê Trung Hiếu, Nguyễn Tất Đạt, Nguyễn Minh Kha. Đặc điểm của nồng độ Non-HDL-C ở bệnh nhân nhồi máu cơ tim cấp. Tạp chí Y Học Thành phố Hồ Chí Minh. 2021;25(2):22-28.
Nguyễn Văn Sĩ, Đinh Quốc Bảo. Kiểm soát Non-HDL-C sau khi đạt mục tiêu LDL-C trên người bệnh đái tháo đường type 2 điều trị ngoại trú. Tạp chí y học Việt Nam. 2024;537(1):337-340.